Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does SOTORASIB Cause Hepatic function abnormal? 80 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 80 reports of Hepatic function abnormal have been filed in association with SOTORASIB (LUMAKRAS). This represents 2.7% of all adverse event reports for SOTORASIB.

80
Reports of Hepatic function abnormal with SOTORASIB
2.7%
of all SOTORASIB reports
12
Deaths
27
Hospitalizations

How Dangerous Is Hepatic function abnormal From SOTORASIB?

Of the 80 reports, 12 (15.0%) resulted in death, 27 (33.8%) required hospitalization, and 2 (2.5%) were considered life-threatening.

Is Hepatic function abnormal Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for SOTORASIB. However, 80 reports have been filed with the FAERS database.

What Other Side Effects Does SOTORASIB Cause?

Non-small cell lung cancer (483) Death (319) Disease progression (314) Diarrhoea (284) Off label use (193) Nausea (98) Non-small cell lung cancer metastatic (93) Hepatotoxicity (91) Fatigue (87) Aspartate aminotransferase increased (71)

What Other Drugs Cause Hepatic function abnormal?

NIVOLUMAB (1,131) PEMBROLIZUMAB (1,079) METHOTREXATE (1,054) CABOZANTINIB S-MALATE (912) CYCLOPHOSPHAMIDE (824) BEVACIZUMAB (769) PACLITAXEL (603) LENVATINIB (528) ATORVASTATIN (520) CYCLOSPORINE (508)

Which SOTORASIB Alternatives Have Lower Hepatic function abnormal Risk?

SOTORASIB vs SOTROVIMAB SOTORASIB vs SOVALDI SOTORASIB vs SOYBEAN OIL SOTORASIB vs SPARSENTAN SOTORASIB vs SPARTALIZUMAB

Related Pages

SOTORASIB Full Profile All Hepatic function abnormal Reports All Drugs Causing Hepatic function abnormal SOTORASIB Demographics